

Kjetil Boye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5053973/publications.pdf>

Version: 2024-02-01

71
papers

1,975
citations

279798

23
h-index

254184

43
g-index

73
all docs

73
docs citations

73
times ranked

3467
citing authors

#	ARTICLE	IF	CITATIONS
1	S100A4 and Metastasis. <i>American Journal of Pathology</i> , 2010, 176, 528-535.	3.8	373
2	Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. <i>BMC Cancer</i> , 2012, 12, 505.	2.6	158
3	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. <i>Nature Communications</i> , 2021, 12, 3230.	12.8	95
4	B7-H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer. <i>International Journal of Cancer</i> , 2012, 131, 2528-2536.	5.1	94
5	Activation of NF- κ B by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes. <i>International Journal of Cancer</i> , 2008, 123, 1301-1310.	5.1	78
6	B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. <i>BMC Cancer</i> , 2014, 14, 602.	2.6	69
7	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	7.1	63
8	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
9	Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2473-2480.	4.1	61
10	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. <i>Acta Oncologica</i> , 2019, 58, 124-128.	1.8	50
11	High expression of the cysteine proteinase legumain in colorectal cancer – Implications for therapeutic targeting. <i>European Journal of Cancer</i> , 2015, 51, 9-17.	2.8	49
12	Disseminated tumour cells as a prognostic biomarker in colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1434-1439.	6.4	47
13	Osteopontin – An important downstream effector of S100A4-mediated invasion and metastasis. <i>International Journal of Cancer</i> , 2011, 129, 780-790.	5.1	46
14	Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF- κ B. <i>BMC Cancer</i> , 2010, 10, 241.	2.6	45
15	Osteopontin is a prognostic biomarker in non-small cell lung cancer. <i>BMC Cancer</i> , 2013, 13, 540.	2.6	45
16	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2617-2624.	4.2	45
17	Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma. <i>Oncology Reports</i> , 2014, 32, 40-44.	2.6	43
18	Nuclear S100A4 is a novel prognostic marker in colorectal cancer. <i>European Journal of Cancer</i> , 2010, 46, 2919-2925.	2.8	42

#	ARTICLE	IF	CITATIONS
19	Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1133-1139.	1.5	40
20	Molecular modelling and simulations in cancer research. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 1-14.	7.4	39
21	High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 840-845.	1.5	39
22	Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour. <i>Pathology</i> , 2021, 53, 713-719.	0.6	29
23	Genotype and risk of tumour rupture in gastrointestinal stromal tumour. <i>British Journal of Surgery</i> , 2018, 105, e169-e175.	0.3	25
24	Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 127-137.	2.5	24
25	Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. <i>Acta Oncologica</i> , 2017, 56, 479-483.	1.8	23
26	Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. <i>BMC Cancer</i> , 2017, 17, 29.	2.6	21
27	EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 667-674.	6.4	20
28	Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. <i>Cancer Biology and Therapy</i> , 2020, 21, 432-440.	3.4	20
29	A novel risk score to predict early and late recurrence in solitary fibrous tumour. <i>Histopathology</i> , 2020, 77, 123-132.	2.9	16
30	Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. <i>Acta Oncologica</i> , 2017, 56, 1317-1323.	1.8	15
31	Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. <i>BMC Cancer</i> , 2012, 12, 333.	2.6	14
32	Expression and clinical significance of Wee1 in colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 12133-12140.	1.8	14
33	Several fusion genes identified by whole transcriptome sequencing in a spindle cell sarcoma with rearrangements of chromosome arm 12q and MDM2 amplification. <i>International Journal of Oncology</i> , 2014, 45, 1829-1836.	3.3	12
34	Prospects for NK Cell Therapy of Sarcoma. <i>Cancers</i> , 2020, 12, 3719.	3.7	12
35	Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach. <i>Annals of Surgical Oncology</i> , 2021, 28, 6837-6845.	1.5	12
36	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 1840-1849.	2.8	11

#	ARTICLE	IF	CITATIONS
37	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. <i>Diagnostic Pathology</i> , 2016, 11, 50.	2.0	10
38	Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). <i>Scientific Reports</i> , 2020, 10, 10853.	3.3	10
39	Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 755-767.	3.3	9
40	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11023-11023.	1.6	9
41	Interferon- γ -Induced Suppression of S100A4 Transcription Is Mediated by the Class II Transactivator. <i>Tumor Biology</i> , 2007, 28, 27-35.	1.8	8
42	Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. <i>ESMO Open</i> , 2017, 2, e000158.	4.5	8
43	Cell-free DNA in blood as a noninvasive insight into the sarcoma genome. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100827.	6.4	8
44	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. <i>Acta Oncol³gica</i> , 2020, 59, 733-740.	1.8	8
45	Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. <i>Clinical Sarcoma Research</i> , 2016, 6, 21.	2.3	7
46	Estimated cumulative radiation dose received by diagnostic imaging during staging and treatment of operable Ewing sarcoma 2005–2012. <i>Pediatric Radiology</i> , 2017, 47, 82-88.	2.0	7
47	Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity. <i>Oncotarget</i> , 2022, 13, 508-517.	1.8	5
48	F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study. <i>Clinical Physiology and Functional Imaging</i> , 2016, 36, 441-446.	1.2	4
49	Added value of 18F-FDG PET-CT in staging of Ewing sarcoma in children and young adults. <i>European Journal of Hybrid Imaging</i> , 2018, 2, .	1.5	4
50	Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. <i>Translational Oncology</i> , 2020, 13, 100793.	3.7	4
51	Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11564-11564.	1.6	4
52	Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients. <i>Tumor Biology</i> , 2012, 33, 73-83.	1.8	3
53	Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 769-776.	4.2	3
54	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. <i>Clinical Sarcoma Research</i> , 2018, 8, .	2.3	3

#	ARTICLE	IF	CITATIONS
55	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. Journal of Clinical Oncology, 2017, 35, 11065-11065.	1.6	2
56	Angiosarcoma of bone: A European Musculoskeletal Oncology Society (EMSOS) multicenter, retrospective study.. Journal of Clinical Oncology, 2019, 37, 11046-11046.	1.6	2
57	Metastases in locally advanced rectal cancer undergoing curatively intended treatment. European Journal of Surgical Oncology, 2021, 47, 2377-2383.	1.0	1
58	Abstract A101: The MetAction trial: long-lasting responses to molecularly matched therapy in end-stage cancer. , 2018, , .		1
59	Performance Characteristics of Seven Neuron-Specific Enolase Assays. Tumor Biology, 2007, 28, 27-35.	1.8	1
60	Abstract 1093: Legumain in colorectal cancer: Unorthodox localization and trafficking. , 2014, , .		1
61	Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.. Journal of Clinical Oncology, 2022, 40, 11535-11535.	1.6	1
62	Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study. Acta Oncol ³ gica, 2022, 61, 793-800.	1.8	1
63	Author response to comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. British Journal of Surgery, 2019, 106, 1102-1103.	0.3	0
64	ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?. Annals of Surgical Oncology, 2021, 28, 6846-6847.	1.5	0
65	Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2021, 39, 11535-11535.	1.6	0
66	Abstract LB-73: Nuclear S100A4 is a novel prognostic marker in colorectal cancer. , 2010, , .		0
67	Abstract 5321: Tyrosine kinase activation by the metastasis promoting protein S100A4. , 2012, , .		0
68	Abstract 2004: S100A4 in colorectal cancer - biological function of nuclear localization. , 2014, , .		0
69	The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice.. Journal of Clinical Oncology, 2017, 35, e14033-e14033.	1.6	0
70	Abstract 5700: CircSarc: Disease monitoring by liquid biopsies in sarcomas. , 2017, , .		0
71	A comprehensive characterization of anatomical and molecular risk factors in gastric gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2020, 38, e23522-e23522.	1.6	0